1. Acknowledgement to Referees

   Acknowledgement to Referees 05 November 2020 Pages: 1487 - 1491

2. The Interplay Between Liver First-Pass Effect and Lymphatic Absorption of Cannabidiol and Its Implications for Cannabidiol Oral Formulations

   • Valentina Franco
   • Pavel Gershkovich
   • Meir Bialer

   Current Opinion 12 August 2020 Pages: 1493 - 1500

3. Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib, and Abemaciclib

   • Stefanie L. Groenland
   • Alejandra Martínez-Chávez
   • Neeltje Steeghs

   Review Article 08 October 2020 Pages: 1501 - 1520

   

4. Intracellular Pharmacokinetics of Pyrimidine Analogues used in Oncology and the Correlation with Drug Action

   • Ellen J. B. Derissen
   • Jos H. Beijnen

   Review Article Open access 16 October 2020 Pages: 1521 - 1550

   

5. Pharmacokinetics in Patients with Cystic Fibrosis: A Systematic Review of Data Published Between 1999 and 2019

   • Pieter-Jan De Sutter
   • Elke Gasthuys
   • An Vermeulen

   Systematic Review 18 August 2020 Pages: 1551 - 1573

   

6. Pharmacokinetic Assessment of Pre- and Post-Oxygenator Vancomycin Concentrations in Extracorporeal Membrane Oxygenation: A Prospective Observational Study

   • Ahmed A. Mahmoud
   • Sean N. Avedissian
   • Marc H. Scheetz

   Original Research Article 28 May 2020 Pages: 1575 - 1587

   

7. Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog^® (Lispro) in Younger Adults and Elderly Patients with Type 1 Diabetes Mellitus: A Randomised Controlled Trial

   • Helle Linnebjerg
   • Qianyi Zhang
   • Jennifer Leohr

   Original Research Article Open access 29 May 2020 Pages: 1589 - 1599

   

8. Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog^® (Lispro) in Patients with Type 2 Diabetes Mellitus: A Phase I Randomised, Crossover Study

   • Jennifer Leohr
   • Mary Anne Dellva
   • Helle Linnebjerg

   Original Research Article Open access 29 May 2020 Pages: 1601 - 1610

   

9. Population Pharmacokinetic Analysis and Exploratory Exposure–Bleeding Rate Relationship of Emicizumab in Adult and Pediatric Persons with Hemophilia A

   • Sylvie Retout
   • Christophe Schmitt
   • Nicolas Frey

   Original Research Article Open access 05 June 2020 Pages: 1611 - 1625

   

10. Validation of a Drug Transporter Probe Cocktail Using the Prototypical Inhibitors Rifampin, Probenecid, Verapamil, and Cimetidine

    • Sabrina T. Wiebe
    • Thomas Giessmann
    • Peter Stopfer

    Original Research Article Open access 05 June 2020 Pages: 1627 - 1639

    

11. Comment on “Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab”

    • Jialing Liu
    • Aliza Anwar Memon
    • Andrew Siedlecki

    Letter to the Editor 28 October 2020 Pages: 1641 - 1643

    

12. Author’s Reply to Liu et al.: “Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab”

    • Kioa Lente Wijnsma
    • Rob ter Heine
    • Roger J. Brüggemann

    Letter to the Editor 28 October 2020 Pages: 1645 - 1646

13. Correction to: Drug–Drug Interactions with Direct Oral Anticoagulants

    • Kathrin I. Foerster
    • Simon Hermann
    • Walter E. Haefeli

    Correction Open access 30 October 2020 Pages: 1647 - 1647